AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33705179 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 295
Study 33705179 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSAAF program
Number of subjects: 295
Study 33705179 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline racial discrimination
Number of subjects: 295
Study 33705179 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in PPB
Number of subjects: 295
Study 32848365 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C 1 g administered 10 minutes after induction of anesthesia, 10 minutes before cardiac reanimation, and at the moment of sternal closure
Number of subjects: 70
Study 32848365 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C 1 g administered
Number of subjects: 70
Study 32848365 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline injection)
Number of subjects: 70
Study 32770782 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 34
Study 32770782 — intervention group
Group type: COMPARATOR
Intervention: Control (routine FUE procedure)
Number of subjects: 34
Study 35322777 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk oral care
Number of subjects: 0
Study 35322777 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate solution for oral care
Number of subjects: 0
Study 33730257 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic baths with 4.5–9 × 10^9 CFU/liter
Number of subjects: 22
Study 34971214 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (pulsed transcranial and intraocular 1068nm near-infrared light)
Number of subjects: 100
Study 34971214 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 100
Study 32149424 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg APT‐1011 BID
Number of subjects: 24
Study 32149424 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mg APT‐1011 QD
Number of subjects: 24
Study 32149424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 33713384 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (3 g)
Number of subjects: 437
Study 33713384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study 33148357 — intervention group
Group type: EXPERIMENTAL
Intervention: Outlook intervention
Number of subjects: 135
Study 33148357 — intervention group
Group type: COMPARATOR
Intervention: Relaxation meditation (RM)
Number of subjects: 135
Study 37216189 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-focus (2 mm) SWL
Number of subjects: 135
Study 37216189 — intervention group
Group type: COMPARATOR
Intervention: Wide-focus (8 mm) SWL
Number of subjects: 135
Study 32886237 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic gastrectomy (SLG)
Number of subjects: 101
Study 32886237 — intervention group
Group type: COMPARATOR
Intervention: Multi-port laparoscopic gastrectomy (MLG)
Number of subjects: 101
Study 34238308 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day NMN
Number of subjects: 48
Study 34238308 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day NMN
Number of subjects: 48
Study 34238308 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg/day NMN
Number of subjects: 48
Study 34238308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 32282603 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of double-balloon device after 6 hours
Number of subjects: 197
Study 32282603 — intervention group
Group type: COMPARATOR
Intervention: Removal of double-balloon device after 12 hours
Number of subjects: 197
Study 35609974 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated flow diverter p64 MW HPC under single antiplatelet treatment (SAPT)
Number of subjects: 0
Study 35609974 — intervention group
Group type: COMPARATOR
Intervention: Bare flow diverter p64 MW under dual antiplatelet treatment (DAPT)
Number of subjects: 0
Study 34226917 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative machine learning framework called Enhancer-IF
Number of subjects: 8
Study 34226917 — intervention group
Group type: COMPARATOR
Intervention: Baseline models using five commonly used ML methods
Number of subjects: 8
Study 36100795 — intervention group
Group type: EXPERIMENTAL
Intervention: IV 400 mg ibuprofen
Number of subjects: 124
Study 36100795 — intervention group
Group type: COMPARATOR
Intervention: IV 20 mg tenoxicam
Number of subjects: 124
Study 34384882 — intervention group
Group type: COMPARATOR
Intervention: Continuous letrozole (2.5 mg/day for 5 years)
Number of subjects: 4884
Study 34384882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent letrozole (2.5 mg/day for 9 months followed by a 3-month interruption in years 1-4 and then 2.5 mg/day during all of year 5)
Number of subjects: 4884
Study 34384882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Continuous and Intermittent letrozole)
Number of subjects: 4884
Study 34384882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent letrozole
Number of subjects: 4884
Study 35377717 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenzilumab
Number of subjects: 0
Study 35377717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34599744 — intervention group
Group type: EXPERIMENTAL
Intervention: ART + Brix3000
Number of subjects: 20
Study 34599744 — intervention group
Group type: COMPARATOR
Intervention: ART
Number of subjects: 20
Study 34375362 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-guided anesthesia with sevoflurane adjusted to maintain a BIS index value between 40 and 60, Suppression Ratio (SR) at 0%, and direct EEG display without suppression time.
Number of subjects: 0
Study 34375362 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving sevoflurane to achieve an age-adjusted minimum alveolar concentration of [0.8-1.2].
Number of subjects: 0
Study 34375362 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-guided anesthesia
Number of subjects: 0
Study 34375362 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32187503 — intervention group
Group type: EXPERIMENTAL
Intervention: 4D-calculated dose
Number of subjects: 20
Study 32187503 — intervention group
Group type: COMPARATOR
Intervention: 3D plan
Number of subjects: 20
Study 35644931 — intervention group
Group type: EXPERIMENTAL
Intervention: Tradipitant 85 mg b.i.d. for 9 days
Number of subjects: 24
Study 35644931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32353592 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 225
Study 32353592 — intervention group
Group type: COMPARATOR
Intervention: High ligation and stripping (HLS)
Number of subjects: 225
Study 32353592 — intervention group
Group type: COMPARATOR
Intervention: Conservative hemodynamic cure for venous insufficiency (CHIVA)
Number of subjects: 225
Study 32767636 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD digital intervention platform
Number of subjects: 1856
Study 32767636 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1856
Study 36218354 — intervention group
Group type: EXPERIMENTAL
Intervention: Avdoralimab
Number of subjects: 207
Study 36218354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 33187948 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg oral amoxicillin before and after surgery
Number of subjects: 92
Study 33187948 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg oral amoxicillin after surgery alone
Number of subjects: 92
Study 33187948 — intervention group
Group type: COMPARATOR
Intervention: Placebo before and after surgery
Number of subjects: 92
Study 35576560 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (patient education and exercise therapy using a mobile messaging app)
Number of subjects: 99
Study 35576560 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (usual medical care with pharmacological treatment)
Number of subjects: 99
Study 34378869 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandplay therapy
Number of subjects: 60
Study 35816140 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% HRmax warm-up protocol
Number of subjects: 34
Study 35816140 — intervention group
Group type: COMPARATOR
Intervention: 60% HRmax warm-up protocol
Number of subjects: 34
Study 35816140 — intervention group
Group type: EXPERIMENTAL
Intervention: RSA performance with 90% HRmax
Number of subjects: 34
Study 35816140 — intervention group
Group type: COMPARATOR
Intervention: RSA performance with 60% HRmax
Number of subjects: 34
Study 33853796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (received additional consultations based on diabetes distress scores)
Number of subjects: 80
Study 33853796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 80
Study 33853796 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard care)
Number of subjects: 80
Study 32289541 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered education
Number of subjects: 296
Study 32289541 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face education
Number of subjects: 296
Study 35114993 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporotic fracture prevention program (OFRA) including falls prevention exercise classes, DXA scan, and safety consultation.
Number of subjects: 9408
Study 35114993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 9408
Study 33864917 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hydroxychloroquine (400 mg once, followed by 200 mg/day)
Number of subjects: 3037
Study 33864917 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine throat spray (3 times/day, 270 µg/day)
Number of subjects: 3037
Study 33864917 — intervention group
Group type: COMPARATOR
Intervention: Oral zinc (80 mg/day)/vitamin C (500 mg/day) combination
Number of subjects: 3037
Study 33864917 — intervention group
Group type: COMPARATOR
Intervention: Oral ivermectin (12 mg once)
Number of subjects: 3037
Study 33864917 — intervention group
Group type: COMPARATOR
Intervention: Oral vitamin C (500 mg/day)
Number of subjects: 3037
Study 35383545 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention activating self-transcendence values
Number of subjects: 140
Study 35383545 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 140
Study 32862688 — intervention group
Group type: EXPERIMENTAL
Intervention: ATTUNE
Number of subjects: 74
Study 32862688 — intervention group
Group type: COMPARATOR
Intervention: PFC-sigma
Number of subjects: 74
Study 36209663 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher environmental sensitivity group
Number of subjects: 503
Study 36209663 — intervention group
Group type: COMPARATOR
Intervention: Low environmental sensitivity group
Number of subjects: 503
Study 34417274 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day course of oral amoxicillin (according to WHO weight bands) provided by community level health workers (CLHWs) in intervention clusters.
Number of subjects: 2312
Study 34417274 — intervention group
Group type: COMPARATOR
Intervention: Standard community case management (assess and refer after pre-referral antibiotic dose) in control clusters.
Number of subjects: 2312
Study 32693740 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D
Number of subjects: 20
Study 32693740 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 20
Study 35215507 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal hemoglobin concentration 100-110 g/L
Number of subjects: 3748
Study 35215507 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal hemoglobin concentration <70 g/L
Number of subjects: 3748
Study 35215507 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal hemoglobin concentration >130 g/L
Number of subjects: 3748
Study 35215507 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal hemoglobin concentration <70 g/L or >130 g/L
Number of subjects: 3748
Study 33368237 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured delivery preparation education
Number of subjects: 160
Study 33368237 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured delivery preparation education)
Number of subjects: 160
Study 33270142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical headgear treatment for 2 years
Number of subjects: 67
Study 33270142 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 67
Study 35966784 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulforaphane (SFN)
Number of subjects: 144
Study 35966784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 33144350 — intervention group
Group type: EXPERIMENTAL
Intervention: i-CONTENT tool
Number of subjects: 49
Study 35048309 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-promotion intervention
Number of subjects: 0
Study 33246001 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD group
Number of subjects: 33
Study 32093635 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitivity for type 1 algorithm (ratio of type 1 to type 2 codes ≥ 4, or at least 1 insulin prescription within 90 days)
Number of subjects: 15297
Study 32093635 — intervention group
Group type: EXPERIMENTAL
Intervention: High PPV for type 1 algorithm (ratio of type 1 to type 2 codes ≥ 4, and multiple daily injections with no other glucose‐lowering medication prescription)
Number of subjects: 15297
Study 32093635 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized algorithm (ratio of type 1 to type 2 codes ≥ 4, and at least 1 insulin prescription within 90 days)
Number of subjects: 15297
Study 32093635 — intervention group
Group type: EXPERIMENTAL
Intervention: All algorithms for T2D classification
Number of subjects: 15297
Study 35684083 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-Restricted Feeding (TRF)
Number of subjects: 41
Study 35684083 — intervention group
Group type: COMPARATOR
Intervention: Usual Feeding Pattern (UFP)
Number of subjects: 41
Study 34523063 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine extended-release capsules (viloxazine ER; Qelbree™) 100-600 mg/day for 6-8 weeks
Number of subjects: 1154
Study 34523063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1154
Study 36282205 — intervention group
Group type: EXPERIMENTAL
Intervention: S.T.O.P. F2 contact lenses
Number of subjects: 0
Study 36282205 — intervention group
Group type: EXPERIMENTAL
Intervention: S.T.O.P. DT contact lenses
Number of subjects: 0
Study 36282205 — intervention group
Group type: COMPARATOR
Intervention: MiSight contact lenses
Number of subjects: 0
Study 34417215 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction and cast immobilisation (long arm cast for 6 weeks)
Number of subjects: 78
Study 34417215 — intervention group
Group type: COMPARATOR
Intervention: Flexible intramedullary nails (immobilised in a collar and cuff sling for 4 weeks)
Number of subjects: 78
Study 35614368 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSPER intervention
Number of subjects: 197
Study 35614368 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 197
Study 32211908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) injection
Number of subjects: 18
Study 32211908 — intervention group
Group type: COMPARATOR
Intervention: Laser photocoagulation
Number of subjects: 18
Study 32289159 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily
Number of subjects: 27395
Study 32289159 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg once daily
Number of subjects: 27395
Study 32792252 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR at a dose of 300 mg once daily
Number of subjects: 505
Study 35099359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-i) with therapist guidance
Number of subjects: 133
Study 35099359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-i) without therapist guidance
Number of subjects: 133
Study 35099359 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group receiving unguided treatment after a delay
Number of subjects: 133
Study 33932626 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interview (MI)
Number of subjects: 52
Study 33932626 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study 37877914 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-Coated Balloon (SCB)
Number of subjects: 121
Study 37877914 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-Coated Balloon (PCB)
Number of subjects: 121
Study 33491436 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma separation
Number of subjects: 80
Study 33491436 — intervention group
Group type: COMPARATOR
Intervention: Acute isovolumic hemodilution
Number of subjects: 80
Study 34289212 — intervention group
Group type: EXPERIMENTAL
Intervention: ConquerFear-Group (CF-G)
Number of subjects: 27
Study 34289212 — intervention group
Group type: COMPARATOR
Intervention: Active Control (AC) - relaxation training
Number of subjects: 27
Study 34201810 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 22
Study 34201810 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 22
Study 34467669 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition counselling using a digital job aid
Number of subjects: 1500
Study 34467669 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (comparison arm)
Number of subjects: 1500
Study 33494844 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake (936 mg/day)
Number of subjects: 150
Study 33494844 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium intake (315 mg/day)
Number of subjects: 150
Study 33494844 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorus intake (1350 mg/day)
Number of subjects: 150
Study 33494844 — intervention group
Group type: COMPARATOR
Intervention: Total calcium intake (1026 mg/day)
Number of subjects: 150
Study 33494844 — intervention group
Group type: COMPARATOR
Intervention: Dietary magnesium intake (331 mg/day)
Number of subjects: 150
Study 33494844 — intervention group
Group type: COMPARATOR
Intervention: Dietary phosphorus intake (1402 mg/day)
Number of subjects: 150
Study 33494844 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium, magnesium, and phosphorus intakes
Number of subjects: 150
Study 33494844 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactions between intakes of these minerals and total fat
Number of subjects: 150
Study 32342519 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA-based prognostic signature
Number of subjects: 0
Study 32342519 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk signature-based nomogram model
Number of subjects: 0
Study 32342519 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-1229-3p
Number of subjects: 0
Study 34687053 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc Blue (RCB) size 25, 0.08 taper
Number of subjects: 40
Study 34687053 — intervention group
Group type: EXPERIMENTAL
Intervention: XP-endo Shaper (XPS) size 30, 0.01 taper
Number of subjects: 40
Study 34687053 — intervention group
Group type: EXPERIMENTAL
Intervention: R-Motion (RM) size 30, 0.04 taper
Number of subjects: 40
Study 34687053 — intervention group
Group type: EXPERIMENTAL
Intervention: HyFlex CM (HFX) size 30, 0.04 taper
Number of subjects: 40
Study 33295974 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 0
Study 33295974 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib-bevacizumab
Number of subjects: 0
Study 33295974 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0
Study 33295974 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 0
Study 33295974 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 35852825 — intervention group
Group type: COMPARATOR
Intervention: Autoclaving only (AU)
Number of subjects: 80
Study 35852825 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% sodium hypochlorite (NaOCl) + AU
Number of subjects: 80
Study 35852825 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrochemical treatment (EC) + AU
Number of subjects: 80
Study 35852825 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl + EC + AU
Number of subjects: 80
Study 35852825 — intervention group
Group type: COMPARATOR
Intervention: Positive control (contaminated without any treatment)
Number of subjects: 80
Study 35852825 — intervention group
Group type: COMPARATOR
Intervention: Negative controls (new unused HAs)
Number of subjects: 80
Study 34310172 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg twice daily
Number of subjects: 533
Study 34310172 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib 420 mg once daily
Number of subjects: 533
Study 34310172 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Number of subjects: 533
Study 34310172 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 533
Study 35686579 — intervention group
Group type: COMPARATOR
Intervention: IBS normal threshold (IBS-NT) cluster
Number of subjects: 80
Study 35686579 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS increased threshold (IBS-IT) cluster
Number of subjects: 80
Study 33770710 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS over DMPFC
Number of subjects: 33
Study 33770710 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 33
Study 35793183 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebral Body Tethering (VBT)
Number of subjects: 31
Study 35793183 — intervention group
Group type: COMPARATOR
Intervention: Posterior Spinal Instrumentation (PI)
Number of subjects: 31
Study 33479800 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) after 60 seconds
Number of subjects: 110
Study 33479800 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (ECC) within 30 seconds
Number of subjects: 110
Study 32362226 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile personal health record application (mPHR)
Number of subjects: 311